Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChemoMetec ASOCSE:CHEMM +1.93%98 3-Year EBITDA Growth Rate is 5.20% as of Dec. 2025, which is 81% below its 10-year median of 27.50. GuruFocus rates OCSE:CHEMM with a GF Score™ of 98/100 and a GF Value™ of kr532.28 (Fairly Valued). The stock has 2 warning signs investors should review. Among 690 Medical Devices & Instruments companies, ChemoMetec AS ranks worse than 55.65% on this metric.
During the past 12 months, ChemoMetec AS's average EBITDA Per Share Growth Rate was 8.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 19.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 38.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of ChemoMetec AS was 77.50% per year. The lowest was -86.50% per year. And the median was 27.50% per year.
ChemoMetec AS (OCSE:CHEMM) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
ChemoMetec AS 3-Year EBITDA Growth Rate Related Terms
OCSE:CHEMM vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, ChemoMetec AS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's 3-Year EBITDA Growth Rate falls into.
ChemoMetec AS 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.20% mean?
ChemoMetec AS (OCSE:CHEMM) has a 3-Year EBITDA Growth Rate of 5.20% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ChemoMetec AS and its competitors. This is 81% below median its historical median of 27.50. According to the industry distribution chart, ChemoMetec AS ranks #384 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 55.7%.
Is ChemoMetec AS's 3-Year EBITDA Growth Rate too high?
ChemoMetec AS's current 3-Year EBITDA Growth Rate of 5.20% is 81% below median its 10-year median of 27.50. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. ChemoMetec AS's value of 5.20% is 35.8% below this industry median. Based on the distribution chart, ChemoMetec AS ranks #384 out of 690 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ChemoMetec AS has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #384 out of 690 companies for 3-Year EBITDA Growth Rate. This places ChemoMetec AS in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. ChemoMetec AS's value of 5.20% is 35.8% below this benchmark. While the company's 10-year median is 27.50 vs. the industry median of 8.10, ChemoMetec AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current 3-Year EBITDA Growth Rate of 5.20% is 35.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current 3-Year EBITDA Growth Rate is 5.20%, which is 81% below median its own 10-year median of 27.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Fairly Valued. The stock's GF Value™ is kr532.28, compared to a current price of kr501.50 — trading 5.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 5.20%, which is 81% below median its 10-year median of 27.50 and 35.8% below the Medical Devices & Instruments industry median of 8.10. ChemoMetec AS's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current 3-Year EBITDA Growth Rate is 5.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr501.50 is trading 5.8% below its estimated GF Value™ of kr532.28.
GuruFocus considers ChemoMetec AS to be Fairly Valued.
Key valuation signals for OCSE:CHEMM:
3-Year EBITDA Growth Rate: 5.20% (81% below median its 10-year median of 27.50)
GF Value™: kr532.28 vs. price of kr501.50 (5.8% below fair value)
Industry Position: 35.8% below the Medical Devices & Instruments median (#384 of 690)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
98GF Score
Get the complete analysis for OCSE:CHEMM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
